TABLE 1.

Demographics of Study Population

DemographicSCD (n = 38)AD (n = 24)
Sex (n)
 Female1611
 Male2213
Age at baseline (y)65 ± 766 ± 7
Age at follow-up (y)67 ± 768 ± 7
Time between PET scans (y)2.1 ± 0.3*2.2 ± 0.3*
MMSE at baseline29 ± 1*24 ± 3*
Aβ-positive† at baseline (n)12/38*24/24*
Aβ-positive† at follow-up (n)16/38*NA
APOE4 allele carriers (n)12/38*17/22 (2 unknown)*

  • ↵* Significant differences (P < 0.05) between diagnostic groups.

  • ↵† SCD subjects were classified as Aβ-positive as evidenced by substantial Aβ pathology after 50- to 70-min SUVr 18F-florbetapir Aβ PET scan visual assessment, and mild cognitive impairment/AD patients were classified as Aβ-positive as evidenced by cerebrospinal fluid biomarkers for AD (i.e., cerebrospinal fluid Aβ1–42 < 813 ng/L) or positive Aβ PET (18F-PiB or 18F-florbetaben) findings by visual assessment.

  • MMSE = mini mental state examination; NA = not available.

  • Mean ± SD are provided, unless otherwise indicated.